Market Cap 814.31M
Revenue (ttm) 403.14M
Net Income (ttm) -22.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.63%
Debt to Equity Ratio -0.50
Volume 10,821,199
Avg Vol 14,495,229
Day's Range N/A - N/A
Shares Out 257.69M
Stochastic %K 50%
Beta 1.07
Analysts Hold
Price Target $2.91

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
Gary9912
Gary9912 Jun. 25 at 1:51 AM
1 · Reply
JasonZemanskyPhD
JasonZemanskyPhD Jun. 24 at 6:43 PM
$ESPR braaaaaaaa !!!
0 · Reply
JasonZemanskyPhD
JasonZemanskyPhD Jun. 24 at 6:42 PM
$ESPR you cant go up but you cant go down when the market is down. there is some Positive in owning this shit
0 · Reply
Albertwest
Albertwest Jun. 24 at 5:35 PM
$ESPR Markman hearing is set for July 7th right before the special meeting. There’s also a bench trial date set for August 2027 if it goes that far. My guess is that if Markman goes well for Esperion, Sandoz settles like the other defendants did. If it goes poorly, this could actually go to trial.
1 · Reply
Rustyton
Rustyton Jun. 24 at 2:25 PM
$ESPR blockbuster drug, scam management and stock
0 · Reply
Rob37F
Rob37F Jun. 24 at 12:04 PM
$ESPR I received this message from a search firm yesterday. I’m sure people are jumping ship with the deal on the table - no one likes uncertainty. However, it does say it’s a brand new position. I’m responding - definitely want to hear more.
3 · Reply
BBRC
BBRC Jun. 24 at 4:51 AM
$ESPR If ISS and GL take the time to review this go private deal they will recommend against it. A recommendation against the deal is necessary to get a bump and/or competing bid. Fingers crossed that they do their job. Their reports will be out any day now.
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 24 at 4:31 AM
$ESPR And it begins.
1 · Reply
Dr_Vinnie_Boombatz
Dr_Vinnie_Boombatz Jun. 23 at 8:28 PM
$ESPR Paging Dr. Galper.
1 · Reply
Gregg617
Gregg617 Jun. 23 at 8:05 PM
$ESPR My day $3.16….$3.15…$3.16…$3.15…$3.16…..$3.17….here we go….$3.16
1 · Reply
Latest News on ESPR
Esperion Therapeutics Proxy statement: Proxy filing

Jun 16, 2026, 8:00 AM EDT - 9 days ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 17 days ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 27 days ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Transcript: AGM 2026

May 28, 2026, 8:00 AM EDT - 4 weeks ago

Esperion Therapeutics Transcript: AGM 2026


Esperion Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 6 weeks ago

Esperion Therapeutics Quarterly report: Q1 2026


Esperion downgraded to Hold from Buy at Needham

2026-05-04T19:10:14.000Z - 7 weeks ago

Esperion downgraded to Hold from Buy at Needham


Esperion Therapeutics Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T19:26:03.000Z - 7 weeks ago

Esperion downgraded to Hold from Buy at Jefferies


Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T15:12:52.000Z - 7 weeks ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright


Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 7 weeks ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion to be Acquired by ARCHIMED

May 1, 2026, 7:00 AM EDT - 7 weeks ago

Esperion to be Acquired by ARCHIMED


Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Esperion to Report First Quarter 2026 Financial Results on May 7


Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Proxy statement: Proxy filing


Esperion showcases new data from CLEAR Outcomes trial

2026-03-30T13:21:46.000Z - 3 months ago

Esperion showcases new data from CLEAR Outcomes trial


Esperion price target raised to $5 from $4 at Citizens

2026-03-13T09:36:20.000Z - 3 months ago

Esperion price target raised to $5 from $4 at Citizens


Esperion Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025


Esperion Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Annual report: Q4 2025


Esperion Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Earnings release: Q4 2025


Esperion Therapeutics Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Esperion Therapeutics Slides: Q4 2025


Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:52.000Z - 3 months ago

Esperion reports Q4 EPS 22c, consensus 28c


Esperion Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Esperion Therapeutics Slides: Corporate presentation


Esperion Therapeutics Transcript: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Transcript: M&A announcement


Esperion Therapeutics Press release: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Press release: M&A announcement


Esperion Therapeutics Slides: M&A announcement

Mar 3, 2026, 8:00 AM EST - 4 months ago

Esperion Therapeutics Slides: M&A announcement


Esperion signs definitive acquisition of Corstasis Therapeutics

2026-03-03T11:05:38.000Z - 4 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics


Esperion reaches settlement agreement with Alkem

2026-02-17T13:16:28.000Z - 4 months ago

Esperion reaches settlement agreement with Alkem


Esperion Therapeutics Transcript: KOL Event

Nov 11, 2025, 2:00 PM EST - 8 months ago

Esperion Therapeutics Transcript: KOL Event


Esperion Therapeutics Slides: KOL Event

Nov 11, 2025, 2:00 PM EST - 8 months ago

Esperion Therapeutics Slides: KOL Event


Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025


Esperion Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Quarterly report: Q3 2025


Esperion Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Earnings release: Q3 2025


Esperion Therapeutics Slides: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Esperion Therapeutics Slides: Q3 2025


Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 9 months ago

Esperion Announces Pricing of Public Offering of Common Stock


Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 9 months ago

Esperion Announces Proposed Public Offering of Common Stock


Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025


Esperion Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Quarterly report: Q2 2025


Esperion Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Earnings release: Q2 2025


Esperion Therapeutics Slides: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Esperion Therapeutics Slides: Q2 2025


Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 1 year ago

Esperion Appoints Craig Thompson to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025


Esperion Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Quarterly report: Q1 2025


Esperion Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings release: Q1 2025


Esperion Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Q1 2025


Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update


Esperion Therapeutics Press release: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Press release: Status Update


Esperion Therapeutics Slides: Status Update

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Slides: Status Update


Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing


Esperion Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Proxy statement: Proxy Filing


Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024


Esperion Therapeutics Annual report: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Annual report: Q4 2024


Esperion Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q4 2024


Esperion Therapeutics Slides: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q4 2024


Esperion Therapeutics Transcript: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event


Esperion Therapeutics Slides: KOL Event

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Slides: KOL Event


Esperion Therapeutics Slides: FY 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Slides: FY 2025


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing


Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024


Esperion Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Quarterly report: Q3 2024


Esperion Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings release: Q3 2024


Esperion Therapeutics Slides: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Slides: Q3 2024


Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024


Esperion Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Quarterly report: Q2 2024


Esperion Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Earnings release: Q2 2024


Esperion Therapeutics Slides: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Q2 2024


Esperion Therapeutics Slides: Corporate Presentation

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Esperion Therapeutics Slides: Corporate Presentation


Gary9912
Gary9912 Jun. 25 at 1:51 AM
1 · Reply
JasonZemanskyPhD
JasonZemanskyPhD Jun. 24 at 6:43 PM
$ESPR braaaaaaaa !!!
0 · Reply
JasonZemanskyPhD
JasonZemanskyPhD Jun. 24 at 6:42 PM
$ESPR you cant go up but you cant go down when the market is down. there is some Positive in owning this shit
0 · Reply
Albertwest
Albertwest Jun. 24 at 5:35 PM
$ESPR Markman hearing is set for July 7th right before the special meeting. There’s also a bench trial date set for August 2027 if it goes that far. My guess is that if Markman goes well for Esperion, Sandoz settles like the other defendants did. If it goes poorly, this could actually go to trial.
1 · Reply
Rustyton
Rustyton Jun. 24 at 2:25 PM
$ESPR blockbuster drug, scam management and stock
0 · Reply
Rob37F
Rob37F Jun. 24 at 12:04 PM
$ESPR I received this message from a search firm yesterday. I’m sure people are jumping ship with the deal on the table - no one likes uncertainty. However, it does say it’s a brand new position. I’m responding - definitely want to hear more.
3 · Reply
BBRC
BBRC Jun. 24 at 4:51 AM
$ESPR If ISS and GL take the time to review this go private deal they will recommend against it. A recommendation against the deal is necessary to get a bump and/or competing bid. Fingers crossed that they do their job. Their reports will be out any day now.
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 24 at 4:31 AM
$ESPR And it begins.
1 · Reply
Dr_Vinnie_Boombatz
Dr_Vinnie_Boombatz Jun. 23 at 8:28 PM
$ESPR Paging Dr. Galper.
1 · Reply
Gregg617
Gregg617 Jun. 23 at 8:05 PM
$ESPR My day $3.16….$3.15…$3.16…$3.15…$3.16…..$3.17….here we go….$3.16
1 · Reply
OldManLogan
OldManLogan Jun. 23 at 3:19 PM
$ESPR Ah, I get it now, you were advising people to sell ESPR shortly before it went up 60%, no wonder you're a bitter individual. Easy: Click "BLOCK"
0 · Reply
OldManLogan
OldManLogan Jun. 23 at 3:14 PM
$ESPR $ICU Are you serious, son? lmao. ESPR's drug WILL absolutely be a blockbuster, the problem was that management and private equity quite literally stole the company before shareholders could benefit from that. I had over 200,000 shares in ESPR and made close to $1.50 per share in profit (and traded a few as well) So I call that a successful investment (clipped only by management's malfeasance) Is your problem with me or $ICU because with Seastar you are talking a company valued at $12 million dollar that could easily be doing $50M in the first year its product's approved in adults and easily $100M+ the year after that... even conservatively it's undervalued by at least 10X. Throwing darts? LMAO. I do deep research into every company I invest in. But hey, you do you, lol.
2 · Reply
Gary9912
Gary9912 Jun. 23 at 2:52 PM
$ESPR Is this the new Bitcoin? (Storage of wealth)🤷‍♂️
1 · Reply
MrPeter
MrPeter Jun. 23 at 2:04 PM
$ESPR 3.17!
0 · Reply
Rescueoncredit
Rescueoncredit Jun. 22 at 9:17 PM
$ESPR anyone remember him?
3 · Reply
Gregg617
Gregg617 Jun. 22 at 6:43 PM
$ESPR bad sign when u are the only volume
1 · Reply
Spaceequiped
Spaceequiped Jun. 22 at 5:24 PM
$ESPR Make sure to login and post before your drive home. Should have held shares, lots and lots. 2 comma lots from many over here. 🫶 health!
1 · Reply
BingusCat
BingusCat Jun. 22 at 2:35 PM
1 · Reply
paivante69
paivante69 Jun. 22 at 1:16 PM
$ESPR A Lógica de Wall Street neste momentoPara um fundo de arbitragem tradicional, gastar milhões em advogados e campanhas públicas por 2 milhões de dólares (um aumento de US$ 0,10) pode não compensar o risco. No entanto, o histórico da Glazer mostra que eles jogam para ganhar incrementos expressivos:A meta realista: Se eles conseguirem forçar um aumento de US$ 0,34 a US$ 0,50 por ação (levando o preço para a casa dos US$ 3,50 - US$ 3,66), eles arrecadam entre 7 e 10 milhões de dólares de lucro extra em pouquíssimas semanas.O risco para a ARCHIMED: Para o comprador (ARCHIMED), pagar 10 ou 15 milhões a mais para selar o negócio e evitar que a fusão de uma empresa inteira colapse na assembleia de 8 de julho é um custo aceitável. É exatamente desse cálculo que a Glazer se aproveita.Estamos na semana decisiva. Se a Glazer for soltar a "bomba" (a carta de oposição), o mercado começará a refletir isso no volume de negociação das ações.
0 · Reply
paivante69
paivante69 Jun. 22 at 1:16 PM
$ESPR Com base na posição massiva que a Glazer Capital detém na Esperion de exatamente 20.975.620 ações (8,15%), a matemática de ganho deles é altamente alavancada.Cada pequena variação no preço final que eles consigam arrancar da ARCHIMED gera milhões de dólares de lucro puro. Veja a escala de ganhos por cada incremento de preço sobre os US$ 3,16 atuais:💰 Tabela de Lucro Extra para a Glazer CapitalPor cada +US$ 0,10 de aumento (Preço: US$ 3,26):📈 +US$ 2,097,562 (~2,1 milhões de dólares) de lucro adicional.Por cada +US$ 0,25 de aumento (Preço: US$ 3,41):📈 +US$ 5,243,905 (~5,2 milhões de dólares) de lucro adicional.Por cada +US$ 0,50 de aumento (Preço: US$ 3,66):📈 +US$ 10.487.810 (~10,5 milhões de dólares) de lucro adicional.Por cada +US$ 1,00 de aumento (Preço: US$ 4,16):📈 +US$ 20,975,620 (~21 milhões de dólares) de lucro adicional.🧠
0 · Reply
paivante69
paivante69 Jun. 22 at 12:50 PM
$ESPR A empresa foi forçada a adiar a assembleia. Para conseguir fechar o negócio, o comprador (CIBC) teve de ceder à pressão e aumentou o preço da proposta duas vezes, gerando um aumento total de mais de 50% no valor final pago por ação (subiu de $47 para $72).2. Atuações Recentes: Oposição a Fusões para Subir PreçosA Glazer repetiu esta estratégia em várias ocasiões nas quais detinha posições majoritárias:Squarespace (Caso Recente): Intervieram ativamente manifestando oposição pública aos termos da aquisição levada a cabo pela empresa de Private equity Permira, visando extrair melhores condições financeiras para as ações.Recursos do QEP: A Glazer moveu uma campanha agressiva tentando travar a venda da empresa para a Diamondback Energy, alegando que o valor oferecido aos acionistas era injusto.ProCap BTC / Columbus Circle (Novembro de 2025): Entraram com um formulário 13D agressivo exigindo a reestruturação imediata ou o cancelamento de uma fusão (SPAC) ciava os investidores públicos.
0 · Reply
paivante69
paivante69 Jun. 22 at 12:49 PM
$ESPR Glazer Capital prova que você tem toda a razão em desconfiar do relatório passivo (13G).No histórico do mercado de fusões e aquisições (M&A), a Glazer Capital é conhecida justamente por uma tática agressiva apelidada de "M&A Activism" ou "Arb-tivism". Eles entram silenciosamente através de um 13G (passivo) ou pequenas posições e, quando ganham massa crítica, mudam as cartas do jogo para forçar a subida do valor.As principais atuações históricas da Glazer mostram exatamente esse padrão:1. O Caso Histórico da PrivateBancorp (O "Modus Operandi")Este é o exemplo mais famoso do fundo:A PrivateBancorp tinha um acordo para ser vendida ao banco canadiano CIBC por um valor fixo.A Glazer montou uma posição relevante e, em cima da hora da assembleia de voto, publicou uma carta aberta arrasadora instando os acionistas a rejeitarem a fusão, alegando que o preço subestimava o valor real da empresa.O Resultado:
0 · Reply